Prostate Cancer
UF Health Initiatives Highlight Cancer Disparities Research During Black History Month
In recognition of Black History Month, the UF Health Cancer Center and the UF department of radiation oncology highlighted ongoing health disparities research and hosted a collaborative and educational prostate cancer event for the Gainesville community. The Community-Partnered Cancer Disparities Research Collaborative One initiative involves the UF…
UF PSMA Study Examines Highly Personalized Approach for Managing Advanced Prostate Cancer
In collaboration with Novartis, the UF Health Radiation Oncology and Genitourinary Oncology teams will begin screening eligible patients for the PSMAfore trial, which examines a new highly targeted, systemic radiopharmaceutical therapy for men with castrate-resistant prostate cancer. Men with metastatic prostate…
New Philips Ambition MR Scanner Unveiled at UF
Combining real-time MRI visualization with adaptive radiotherapy treatment planning and immediate delivery represents the next step in precision tailored cancer therapy, and these advanced high technology treatment techniques can be applied to both the definitive cure of primary tumors and also to the management of recurrent metastasis with ablative control…
Systemic Radioisotope Therapy
PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)* PLUVICTO is radiopharmaceutical used to treat adults with advanced prostate cancer that is prostate-specific membrane antigen–Âpositive (PSMA-positive), metastatic and castration-resistant (mCRPC). PSMA-positive prostate cancers can be detected by a special PET scan. PLUVICTO is a treatment option for PSMA-positive mCRPC that…
Short Course Radiation, SpaceOAR VUE Minimize Side Effects and Promote Quality of Life for UF Prostate Cancer Patients
To further minimize side effects and promote quality of life for prostate cancer patients, the Department of Radiation Oncology has combined SpaceOAR VUE hydrogel administration with a 20-day Moderate Hypofractionated prostate cancer radiotherapy course at the UF Health Medical Oncology – Davis Cancer Pavilion. SpaceOAR VUE is a next-generation hydrogel…
Professor Leads Global Prostate Cancer Initiatives in Florida and Africa
Folakemi T. Odedina, PhD (shown left), Joint Professor in Radiation Oncology, Pharmacotherapy and Translational Research, has been appointed (non-paid appointment) by the Nigeria National Universities Commission to lead an initiative that will bridge Nigerian Academics to Academics in the Diaspora willing to contribute to the Nigerian University System in the…
Short Course Radiation Therapy Now Offered, Cutting Treatment Time in Half
Robert Zlotecki, MD, PhD, UF Radiation Oncology Professor, Vice Chair of Clinical Affairs, and Medical Director, and Assistant Professor Kathryn E. Hitchcock, MD, PhD, are now offering a four-week short course radiation therapy regimen at the UF Davis Cancer Pavilion for patients with low to favorable…
Prostate Cancer and the Use of Proton Therapy
Randal H. Henderson, MD, MBA, UF Radiation Oncology Professor and Associate Medical Director, University of Florida Health Proton Therapy Institute, discusses the benefits of proton therapy in the treatment of prostate cancer. …
Prostate Radiotherapy Patients Begin Receiving SpaceOAR Hydrogel at the Davis Cancer Pavilion
The Department of Radiation Oncology has begun administering SpaceOAR hydrogel in patients undergoing prostate radiotherapy at the UF Health Medical Oncology – Davis Cancer Pavilion. SpaceOAR hydrogel is injected into place prior to the start of radiation treatment. Patients may be awake or asleep under general anesthesia for the procedure.
